[Large-scale production of recombinant adeno-associated virus (rAAV)].
Recombinant adeno-associated virus has been proven to be a promising gene delivery vector for human gene therapy with many advantages. Successful applications of recombinant adeno-associated virus vectors in preclinical and clinical human gene therapies make it become a demanded product. A well-established and large-scale production system is therefore required. Since wild type of adeno-associated virus was well characterized in 1989, progress has been made. Particularly, package system of recombinant adeno-associated virus has been developed to use insect cell instead of human cell. These advances in adeno-associated virus production will allow it to meet the demands of basic research and clinical applications. This review will focus on trends in packaging systems and development on a large scale of recombinant adeno-associated virus production.
Wang
Feng
F
Engineering Research Center of Molecular Medicine, Ministry of Education, Quanzhou 362021, China.
Diao
Yong
Y
Xiao
Weidong
W
Xu
Ruian
R
D000818:Animals; D001709:Biotechnology / Q000379:methods*; D000229:Dependovirus / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007313:Insecta / Q000166:cytology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics; D019065:Virus Assembly
D011994:Recombinant Proteins